Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment

Hideki Shimodaira, Hiroshi Soeda, Keigo Komine, Chikashi Ishioka

Research output: Contribution to journalArticle

Abstract

Anti-EGFR antibodies were designed to inhibit the receptor tyrosine kinase activity of EGFR by directly binding to the extracellular domain. Anti-EGFR antibodies have been approved or will be approved for use in Japan, the USA or Europe. Recently, many studies have investigated molecular markers can predict the response to anti-EGFR antibodies so as to discriminate responders and non-responders. Activating KRAS mutation has been shown to be a potent predictive marker of resistance to anti-EGFR antibodies. Moreover, BRAF mutations, PIK3CA mutations or loss of PTEN have also been shown to be other molecular markers to predict resistance to anti-EGFR antibodies. Further studies must integrate these markers into clinical decisions to use or not use anti-EGFR antibodies.

Original languageEnglish
Pages (from-to)1063-1066
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Volume36
Issue number7
Publication statusPublished - 2009 Jul

Keywords

  • Colorectal cancer
  • EGFR

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment'. Together they form a unique fingerprint.

  • Cite this